Imatinib alone was unable to completely turn-off MAPK signaling in GIST-T1, and PI3K/MAPK signaling in resistant cell lines, suggesting that residual signaling can facilitate survival of GIST cells in the presence of KIT inhibitors. Here, PIK3CA is linked to gastrointestinal stromal tumor.